General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-13 | 2024-03 | -0.21 | -0.25 | -0.04 | -19.05% |
2024-03-27 | 2023-12 | -0.36 | -0.27 | 0.09 | 25.00% |
2023-11-13 | 2023-09 | -0.41 | -0.4 | 0.01 | 2.44% |
2023-08-09 | 2023-06 | -0.45 | -0.46 | -0.01 | -2.22% |
2023-05-08 | 2023-03 | -0.5 | -0.52 | -0.02 | -4.00% |
2023-03-07 | 2022-12 | -0.53 | -0.46 | 0.07 | 13.21% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-09 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-05-16 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-05-08 | HC Wainwright & Co. | Upgrade | Buy | |
2023-04-10 | HC Wainwright & Co. | Upgrade | Buy | |
2023-03-13 | JonesTrading | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2019-03-11 | ARENBERG MICHAEL H. J.D. | Chief Financial Officer | 24.43K | Purchase |
2022-05-23 | AZAB MOHAMMAD | Director | 60.00K | Purchase |
2021-12-06 | BENITO SIMON X | Director | 105.00K | Purchase |
2020-08-31 | BLEICHROEDER LP | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
2022-05-17 | FARFEL GAIL M | Director | 100.00K | Purchase |
2019-06-19 | FIRST EAGLE INVESTMENT MANAGEMENT L L C | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Bleichroeder LP | 2.64M | 13.06M | 9.56% |
2023-06-29 | Ingalls & Snyder | 1.49M | 7.39M | 5.41% |
2023-06-29 | Vanguard Group Inc | 1.02M | 5.05M | 3.70% |
2023-06-29 | Lion Point Capital, LP | 601.66K | 2.98M | 2.18% |
2023-06-29 | CM Management, LLC | 470.00K | 2.33M | 1.70% |
2023-06-29 | Renaissance Technologies, LLC | 362.53K | 1.79M | 1.31% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 663.46K | 3.28M | 2.40% |
2023-06-29 | Vanguard Extended Market Index Fund | 315.07K | 1.56M | 1.14% |
2023-05-30 | Fidelity Extended Market Index Fund | 116.55K | 716.80K | 0.42% |
2023-08-30 | iShares Micro Cap ETF | 57.34K | 175.47K | 0.21% |
2023-05-30 | Fidelity Total Market Index Fund | 37.26K | 229.14K | 0.13% |
2023-05-30 | Fidelity Series Total Market Index Fund | 28.77K | 176.95K | 0.10% |
Split | Date |
---|---|
1 : 10 | 2022-12-06 |
Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi
-- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.
Funny that people still think DRRX has a chance here.
Enough said.